Publicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (8)

2018

  1. Antinuclear antibodies and cancer: A literature review

    Critical Reviews in Oncology/Hematology, Vol. 127, pp. 42-49

2017

  1. Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study

    International Journal of Radiation Oncology Biology Physics, Vol. 97, Núm. 3, pp. 473-480

  2. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial

    Tumor Biology, Vol. 39, Núm. 6

2015

  1. Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer

    PLoS ONE, Vol. 10, Núm. 1

2014

  1. First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study

    British Journal of Cancer, Vol. 111, Núm. 2, pp. 241-248

2012

  1. Upregulation of trefoil factor 3 (TFF3) after rectal cancer chemoradiotherapy is an adverse prognostic factor and a potential therapeutic target

    International Journal of Radiation Oncology Biology Physics, Vol. 84, Núm. 5, pp. 1151-1158

2011

  1. A combined strategy of SAGE and quantitative PCR provides a 13-gene signature that predicts preoperative chemoradiotherapy response and outcome in rectal cancer

    Clinical Cancer Research, Vol. 17, Núm. 12, pp. 4145-4154

2003

  1. Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non-small-cell lung cancer

    Cancer Chemotherapy and Pharmacology, Vol. 52, Núm. 3, pp. 247-252